These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

664 related articles for article (PubMed ID: 31484710)

  • 21. Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS.
    Freedman MS; Brod S; Singer BA; Cohen BA; Hayward B; Dangond F; Coyle PK
    J Neurol; 2020 Jan; 267(1):64-75. PubMed ID: 31559532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis.
    McCool R; Wilson K; Arber M; Fleetwood K; Toupin S; Thom H; Bennett I; Edwards S
    Mult Scler Relat Disord; 2019 Apr; 29():55-61. PubMed ID: 30677733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis.
    Hauser SL; Bar-Or A; Weber MS; Kletzl H; Günther A; Manfrini M; Model F; Mercier F; Petry C; Wing Q; Koendgen H; Smith T; Kappos L
    Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36792367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension.
    Kappos L; Traboulsee A; Li DKB; Bar-Or A; Barkhof F; Montalban X; Leppert D; Baldinotti A; Schneble HM; Koendgen H; Sauter A; Wang Q; Hauser SL
    J Neurol; 2024 Feb; 271(2):642-657. PubMed ID: 37906326
    [TBL] [Abstract][Full Text] [Related]  

  • 25. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.
    Kappos L; Havrdova E; Giovannoni G; Khatri BO; Gauthier SA; Greenberg SJ; You X; Wang P; Giannattasio G
    Mult Scler; 2017 Nov; 23(13):1736-1747. PubMed ID: 28080250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peginterferon beta-1a reduces the evolution of MRI lesions to black holes in patients with RRMS: a post hoc analysis from the ADVANCE study.
    Arnold DL; You X; Castrillo-Viguera C
    J Neurol; 2017 Aug; 264(8):1728-1734. PubMed ID: 28685353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of subcutaneous interferon β-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study.
    De Stefano N; Sormani MP; Stubinski B; Blevins G; Drulovic JS; Issard D; Shotekov P; Gasperini C
    J Neurol Sci; 2012 Jan; 312(1-2):97-101. PubMed ID: 21880336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis.
    Liu Y; Vollmer T; Havrdova E; Riester K; Lee A; Phillips G; Wang P; Sabatella G
    Mult Scler Relat Disord; 2017 Jan; 11():18-24. PubMed ID: 28104250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.
    Havrdová E; Arnold DL; Bar-Or A; Comi G; Hartung HP; Kappos L; Lublin F; Selmaj K; Traboulsee A; Belachew S; Bennett I; Buffels R; Garren H; Han J; Julian L; Napieralski J; Hauser SL; Giovannoni G
    Mult Scler J Exp Transl Clin; 2018; 4(1):2055217318760642. PubMed ID: 29568544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ocrelizumab in pediatric multiple sclerosis.
    Bibinoğlu Amirov C; Saltık S; Yalçınkaya C; Tütüncü M; Saip S; Siva A; Uygunoğlu U
    Eur J Paediatr Neurol; 2023 Mar; 43():1-5. PubMed ID: 36724688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis.
    Samjoo IA; Klotz L; Giovannoni G; Drudge C; Haltner A; Worthington E; Zhao M; Brennan R; Häring DA; Cameron C; Adlard N
    Mult Scler Relat Disord; 2022 Oct; 66():104031. PubMed ID: 35841716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a.
    Kolind S; Abel S; Taylor C; Tam R; Laule C; Li DKB; Garren H; Gaetano L; Bernasconi C; Clayton D; Vavasour I; Traboulsee A
    Neuroimage Clin; 2022; 35():103109. PubMed ID: 35878575
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS.
    Arnold DL; Sprenger T; Bar-Or A; Wolinsky JS; Kappos L; Kolind S; Bonati U; Magon S; van Beek J; Koendgen H; Bortolami O; Bernasconi C; Gaetano L; Traboulsee A
    Mult Scler; 2022 Oct; 28(12):1927-1936. PubMed ID: 35672926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ocrelizumab: A Review in Multiple Sclerosis.
    Lamb YN
    Drugs; 2022 Feb; 82(3):323-334. PubMed ID: 35192158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
    Cohen JA; Comi G; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Huang V; Kappos L;
    Lancet Neurol; 2019 Nov; 18(11):1021-1033. PubMed ID: 31492652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
    Kappos L; Wiendl H; Selmaj K; Arnold DL; Havrdova E; Boyko A; Kaufman M; Rose J; Greenberg S; Sweetser M; Riester K; O'Neill G; Elkins J
    N Engl J Med; 2015 Oct; 373(15):1418-28. PubMed ID: 26444729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
    Comi G; Kappos L; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Ding N; Cohen JA;
    Lancet Neurol; 2019 Nov; 18(11):1009-1020. PubMed ID: 31492651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study.
    Freedman MS; Francis GS; Sanders EA; Rice GP; O'Connor P; Comi G; Duquette P; Metz L; Murray TJ; Bouchard JP; Abramsky O; Pelletier J; O'Brien F; ;
    Mult Scler; 2005 Feb; 11(1):41-5. PubMed ID: 15732265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.
    Sanford M; Lyseng-Williamson KA
    Drugs; 2011 Oct; 71(14):1865-91. PubMed ID: 21942977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.